Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2024-05, Vol.38 (5), p.947-950
Hauptverfasser:	Kantarjian, Hagop, Branford, Susan, Breccia, Massimo, Cortes, Jorge, Haddad, Fadi G., Hochhaus, Andreas, Hughes, Timothy, Issa, Ghayas C., Jabbour, Elias, Nicolini, Franck E., Sasaki, Koji, Xavier-Mahon, Francois
Format:	Artikel
Sprache:	eng
Schlagworte:	692/699/1541/1990/283/1896 692/700/565/1436/1437 Bone marrow Cancer Cancer Research Chronic myeloid leukemia Critical Care Medicine Drug dosages FDA approval Hematology Intensive Interferon Internal Medicine Kinases Leukemia Medical prognosis Medical research Medicine Medicine & Public Health Myeloid leukemia Oncology Perspective Regulatory approval Standard of care Tyrosine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!